

Arie Regev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/751530/publications.pdf>

Version: 2024-02-01

15
papers

540
citations

758635

12
h-index

1058022

14
g-index

15
all docs

15
docs citations

15
times ranked

779
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis B Virus Reactivation After Cytotoxic Chemotherapy: The Disease and Its Prevention. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1076-1081.	2.4	125
2	Drug-Induced Liver Injury and Drug Development: Industry Perspective. <i>Seminars in Liver Disease</i> , 2014, 34, 227-239.	1.8	82
3	Drug rechallenge following drug-induced liver injury. <i>Hepatology</i> , 2017, 66, 646-654.	3.6	50
4	Causality Assessment for Suspected DILI During Clinical Phases of Drug Development. <i>Drug Safety</i> , 2014, 37, 47-56.	1.4	45
5	Drug-Induced Liver Injury in Patients With Preexisting Chronic Liver Disease in Drug Development: How to Identify and Manage?. <i>Gastroenterology</i> , 2016, 151, 1046-1051.	0.6	38
6	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. <i>Journal of Autoimmunity</i> , 2020, 114, 102514.	3.0	37
7	Drug-Induced Liver Injury: Morbidity, Mortality, and Hyâ€™s Law. <i>Gastroenterology</i> , 2014, 147, 20-24.	0.6	36
8	Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 702-713.	1.9	28
9	How to Avoid Being Surprised by Hepatotoxicity at the Final Stages of Drug Development and Approval. <i>Clinics in Liver Disease</i> , 2013, 17, 749-767.	1.0	21
10	Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 90-109.	1.9	21
11	Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. <i>Drug Safety</i> , 2019, 42, 701-711.	1.4	19
12	Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. <i>Drug Safety</i> , 2021, 44, 133-165.	1.4	19
13	Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database. <i>BMC Gastroenterology</i> , 2015, 15, 134.	0.8	10
14	Liver safety assessment in clinical trials of new agents for chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 96-109.	1.0	9
15	Assessment of a Severity-Based Algorithm to Detect Signals of Severe Drug-Induced Liver Injury Using Spontaneous Reporting Database. <i>Pharmaceutical Medicine</i> , 2017, 31, 41-51.	1.0	0